Heath Lukatch
Known title: DirectorCIK: 0001596385
Associated companies
Transaction History
| PCVX | ▲ Buy | Grant | 2,265 | $0 | 6/15/2026 | View on chart |
| PCVX | ▲ Buy | Grant | 3,041 | $0 | 6/12/2025 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 6,000 | $96K | 4/8/2025 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 1,000 | $21K | 4/8/2025 | View on chart |
| PCVX | ▲ Buy | Grant | 1,550 | $0 | 6/6/2024 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 5,000 | $80K | 1/31/2024 | View on chart |
| PCVX | ▼ Sell | Open Market | 5,000 | $358K | 1/31/2024 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 4,000 | $64K | 1/29/2024 | View on chart |
| PCVX | ▼ Sell | Open Market | 4,000 | $270K | 1/29/2024 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 13,000 | $208K | 1/2/2024 | View on chart |
| PCVX | ▼ Sell | Open Market | 1,101 | $69K | 1/2/2024 | View on chart |
| PCVX | ▼ Sell | Open Market | 7,444 | $473K | 1/2/2024 | View on chart |
| PCVX | ▼ Sell | Open Market | 4,164 | $268K | 1/2/2024 | View on chart |
| PCVX | ▼ Sell | Open Market | 291 | $19K | 1/2/2024 | View on chart |
| PCVX | ▲ Buy | Grant | 2,500 | $0 | 6/13/2023 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 315 | $5K | 1/10/2023 | View on chart |
| PCVX | ▼ Sell | Open Market | 233 | $11K | 1/10/2023 | View on chart |
| PCVX | ▼ Sell | Open Market | 82 | $4K | 1/10/2023 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 335 | $5K | 12/12/2022 | View on chart |
| PCVX | ▼ Sell | Open Market | 16 | $678 | 12/12/2022 | View on chart |
| PCVX | ▼ Sell | Open Market | 319 | $14K | 12/12/2022 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 4,335 | $69K | 11/10/2022 | View on chart |
| PCVX | ▼ Sell | Open Market | 335 | $15K | 11/10/2022 | View on chart |
| PCVX | ▼ Sell | Open Market | 4,000 | $185K | 11/10/2022 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 4,000 | $64K | 10/26/2022 | View on chart |
| PCVX | ▼ Sell | Open Market | 4,000 | $153K | 10/26/2022 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 3,015 | $48K | 10/24/2022 | View on chart |
| PCVX | ▼ Sell | Open Market | 3,015 | $106K | 10/24/2022 | View on chart |
| PCVX | ▲ Buy | Grant | 3,125 | $0 | 6/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Vaxcyte VAX-31 clears Phase III OPUS-1 trial endpoints
Vaxcyte announced that its VAX-31 vaccine met all primary endpoints in the pivotal Phase III OPUS-1 trial. This positive data point positions the company for additional readouts expected in the first half of 2027. The stock is currently trading near its 52-week high, reflecting strong market interest in the clinical progress.
Vaxcyte VAX-31 clears Phase III OPUS-1 trial endpoints. Vaxcyte announced that its VAX-31 vaccine met all primary endpoints in the pivotal Phase III OPUS-1 trial. This positive data point positions the company for additional readouts expected in the first half of 2027. The stock is currently trading near its 52-week high, reflecting strong market interest in the clinical progress.